Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
29 Februar 2024 - 12:22PM
Edgar (US Regulatory)
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES
EXCHANGE ACT OF 1934
February, 2024
Commission File Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒
Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes
☐
No ☒
If “Yes” is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED (Registrant) |
|
|
|
Date: February 28, 2024 |
By: |
/s/ K Randhir Singh |
|
|
Name: |
K Randhir Singh |
|
|
Title: |
Company Secretary |
Exhibit
99.1
|
Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com |
February 28, 2024
National Stock Exchange of India Ltd. (Scrip Code:
DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Ref: Disclosure
under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
This is to inform that the wholly owned subsidiary
of the Company, namely, Industrias Químicas Falcon de Mexico, S.A. de C.V., (referred to hereinafter as "Dr. Reddy’s
Mexico") has received an Order from the Superior Chamber of the Federal Court in Administrative Justice, Mexico, pertaining to ongoing
tax litigation. The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015 are as hereunder:
Name of the authority |
: |
The Superior Chamber of the Federal Court in Administrative Justice, Mexico |
Nature and details of the action(s) taken, initiated or order(s) passed |
: |
Dr. Reddy’s Mexico, wholly owned subsidiary of Dr. Reddy’s Laboratories Limited, has received an Order from the Superior Chamber of the Federal Court in Administrative Justice, Mexico pertaining to ongoing tax litigation. |
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority |
: |
Order by electronic jurisdictional bulletin of the Federal Court of Administrative Justice dated February 26, 2024, was received by the Company on February 28, 2024. |
Details of the violation(s)/ contravention(s) committed or alleged to be committed |
: |
The Superior Chamber of the Federal Court in Administrative Justice, Mexico, disallowed certain expenditure claimed by Dr. Reddy’s Mexico for the Calander Years 2006, 2007 and 2008; |
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible |
: |
The Company is evaluating the details of the order and its implications. The Order is in a foreign language (Spanish) and after evaluation of the said Order, the Company will update implication and monetary impact, if any |
The Company will evaluate filing necessary appeal
with the appellate authority in this regard.
This is for your information and records.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
![](https://www.sec.gov/Archives/edgar/data/1135951/000157587224000193/drr0572_ex99-1img02.jpg)
K Randhir Singh
Company Secretary, Compliance Officer & Head-CSR
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
Von Apr 2023 bis Apr 2024